Journal
CURRENT CANCER DRUG TARGETS
Volume 18, Issue 2, Pages 177-187Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1568009617666170222125035
Keywords
Cancer gene therapy; measles virus clinical trials; MV-CEA; MV-NIS; oncolytic measles; virotherapy
Categories
Funding
- National Institutes of Health [T32 CA009666]
- NIH [P50 CA108961, P50 CA 116201, P50 CA 136393, R01 CA 154348, R01 136547]
- NATIONAL CANCER INSTITUTE [R01CA136547, R01CA154348, P50CA108961, P50CA186781, P50CA116201, R01CA200507, P50CA136393, T32CA009666] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Attenuated Edmonston lineage measles virus (MV-Edm) vaccine strains can preferentially infect and lyse a wide variety of cancer cells. Oncolytic MV-Edm derivatives are genetically engineered to express the human carcinoembryonic antigen (MV-CEA virus) or the human sodium iodide symporter (MV-NIS virus) and are currently being tested in clinical trials against ovarian cancer, glioblastoma multiforme, multiple myeloma, mesothelioma, head and neck cancer, breast cancer and malignant peripheral nerve sheath tumors. This review describes the basic and preclinical data that facilitated the clinical translation of MV-Edm strains, and summarizes the clinical results of this oncolytic platform to date. Furthermore, we discuss the latest clinically relevant MV-Edm vector developments and creative strategies for future translational steps.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
